Savitha M. Rao

Array ( [id] => 20377640 [patent_doc_number] => 20250360133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-27 [patent_title] => FORMULATIONS OF VIMSELTINIB [patent_app_type] => utility [patent_app_number] => 19/295254 [patent_app_country] => US [patent_app_date] => 2025-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 231002 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19295254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20067014 [patent_doc_number] => 20250205236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-26 [patent_title] => FORMULATIONS OF VIMSELTINIB [patent_app_type] => utility [patent_app_number] => 19/079070 [patent_app_country] => US [patent_app_date] => 2025-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 231083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19079070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20005895 [patent_doc_number] => 20250144117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => ILOPROST COMPOSITIONS AND FORMULATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 19/018702 [patent_app_country] => US [patent_app_date] => 2025-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19018702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023114 [patent_doc_number] => 20250161336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/980262 [patent_app_country] => US [patent_app_date] => 2024-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18980262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023114 [patent_doc_number] => 20250161336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/980262 [patent_app_country] => US [patent_app_date] => 2024-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18980262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023114 [patent_doc_number] => 20250161336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/980262 [patent_app_country] => US [patent_app_date] => 2024-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18980262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20371205 [patent_doc_number] => 12478619 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => Method of treatment with milsaperidone [patent_app_type] => utility [patent_app_number] => 18/965591 [patent_app_country] => US [patent_app_date] => 2024-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 10810 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18965591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19814981 [patent_doc_number] => 20250073188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/952791 [patent_app_country] => US [patent_app_date] => 2024-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18952791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19814981 [patent_doc_number] => 20250073188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/952791 [patent_app_country] => US [patent_app_date] => 2024-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18952791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798890 [patent_doc_number] => 20250064815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => PARTICULATE COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/949105 [patent_app_country] => US [patent_app_date] => 2024-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18949105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19682321 [patent_doc_number] => 20250000866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => PARTICULATE COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/753759 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18753759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793276 [patent_doc_number] => 12234205 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-02-25 [patent_title] => Sulfonylhydrazide derivatives as anticancer agents [patent_app_type] => utility [patent_app_number] => 18/671935 [patent_app_country] => US [patent_app_date] => 2024-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 10979 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18671935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430929 [patent_doc_number] => 20240299427 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => HALOGENATED PSILOCYBIN DERIVATIVES AND METHODS OF USING [patent_app_type] => utility [patent_app_number] => 18/655793 [patent_app_country] => US [patent_app_date] => 2024-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37520 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18655793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19768396 [patent_doc_number] => 20250049822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/656519 [patent_app_country] => US [patent_app_date] => 2024-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18656519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19855528 [patent_doc_number] => 12258351 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-25 [patent_title] => Sesquiterpenoid derivative and use thereof in preparing broad-spectrum antiviral drug [patent_app_type] => utility [patent_app_number] => 18/625188 [patent_app_country] => US [patent_app_date] => 2024-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 4567 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18625188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402067 [patent_doc_number] => 20240285578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE [patent_app_type] => utility [patent_app_number] => 18/616046 [patent_app_country] => US [patent_app_date] => 2024-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49416 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18616046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19257957 [patent_doc_number] => 12017998 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-06-25 [patent_title] => 5-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/437229 [patent_app_country] => US [patent_app_date] => 2024-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4292 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19707757 [patent_doc_number] => 20250017899 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => METHOD OF TREATING CANCER WITH COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS (HDACI) SUBSTANCES [patent_app_type] => utility [patent_app_number] => 18/431805 [patent_app_country] => US [patent_app_date] => 2024-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18431805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19915158 [patent_doc_number] => 12290503 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Compositions and methods for treating epilepsy, seizures and other conditions [patent_app_type] => utility [patent_app_number] => 18/409952 [patent_app_country] => US [patent_app_date] => 2024-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 9619 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18409952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19550921 [patent_doc_number] => 12134617 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-11-05 [patent_title] => Pyrimido[1'6':1,5]pyrazolo[4,3-c][1,7]naphthyridines as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/409768 [patent_app_country] => US [patent_app_date] => 2024-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8734 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18409768 [rel_patent_id] =>[rel_patent_doc_number] =>)